chemokines. Our data provide evidence for a suppressive immune microenvironment in patients with TRL and suggest promising targets, such as the CXCR2 axis, for its therapeutic intervention.Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first